Answers are grounded in this paper and cite their sources.
Inhibition of the platelet glycoprotein IIb/IIIa receptor with abciximab, together with low-dose, weight-adjusted heparin, markedly reduces the risk of acute ischemic complications in patients undergoing percutaneous coronary revascularization, without increasing the risk of hemorrhage.
No takes yet. Share an insight, caveat, or question.
The EPILOG Investigators (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: